Puma Biotechnology Past Earnings Performance
Past criteria checks 5/6
Puma Biotechnology has been growing earnings at an average annual rate of 73.3%, while the Biotechs industry saw earnings growing at 23.9% annually. Revenues have been declining at an average rate of 1.3% per year. Puma Biotechnology's return on equity is 32.1%, and it has net margins of 17.4%.
Key information
73.30%
Earnings growth rate
73.32%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | -1.34% |
| Return on equity | 32.08% |
| Net Margin | 17.44% |
| Last Earnings Update | 30 Sep 2025 |
Recent past performance updates
Recent updates
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Dec 09
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 13Puma Biotechnology: Step By Step In Making A Transition
Nov 10Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Oct 18Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Sep 11Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
Aug 12We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
Aug 09Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
May 20Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Apr 11Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Mar 10
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
Jan 14Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Dec 16Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Revenue & Expenses Breakdown
How Puma Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 212 | 37 | 69 | 60 |
| 30 Jun 25 | 238 | 48 | 69 | 57 |
| 31 Mar 25 | 233 | 38 | 76 | 55 |
| 31 Dec 24 | 230 | 30 | 80 | 55 |
| 30 Sep 24 | 244 | 23 | 83 | 53 |
| 30 Jun 24 | 219 | 9 | 89 | 52 |
| 31 Mar 24 | 227 | 15 | 89 | 51 |
| 31 Dec 23 | 236 | 22 | 89 | 50 |
| 30 Sep 23 | 229 | 4 | 97 | 51 |
| 30 Jun 23 | 230 | -2 | 98 | 51 |
| 31 Mar 23 | 235 | 5 | 94 | 50 |
| 31 Dec 22 | 228 | 0 | 90 | 52 |
| 30 Sep 22 | 218 | 10 | 87 | 53 |
| 30 Jun 22 | 207 | -34 | 90 | 60 |
| 31 Mar 22 | 201 | -49 | 108 | 67 |
| 31 Dec 21 | 253 | -29 | 116 | 72 |
| 30 Sep 21 | 250 | -48 | 122 | 82 |
| 30 Jun 21 | 255 | -35 | 126 | 86 |
| 31 Mar 21 | 272 | -27 | 116 | 92 |
| 31 Dec 20 | 225 | -60 | 118 | 98 |
| 30 Sep 20 | 235 | -56 | 120 | 104 |
| 30 Jun 20 | 241 | -42 | 122 | 110 |
| 31 Mar 20 | 224 | -82 | 126 | 123 |
| 31 Dec 19 | 272 | -76 | 140 | 133 |
| 30 Sep 19 | 280 | -95 | 151 | 141 |
| 30 Jun 19 | 287 | -92 | 148 | 147 |
| 31 Mar 19 | 284 | -99 | 155 | 154 |
| 31 Dec 18 | 251 | -114 | 146 | 165 |
| 30 Sep 18 | 202 | -147 | 136 | 177 |
| 30 Jun 18 | 145 | -210 | 140 | 190 |
| 31 Mar 18 | 94 | -243 | 125 | 200 |
| 31 Dec 17 | 28 | -292 | 107 | 208 |
| 30 Sep 17 | 6 | -301 | 92 | 214 |
| 30 Jun 17 | 0 | -289 | 74 | 216 |
| 31 Mar 17 | 0 | -278 | 61 | 217 |
| 31 Dec 16 | 0 | -276 | 54 | 223 |
| 30 Sep 16 | 0 | -265 | 47 | 219 |
| 30 Jun 16 | 0 | -260 | 42 | 219 |
| 31 Mar 16 | 0 | -258 | 35 | 224 |
| 31 Dec 15 | 0 | -239 | 32 | 208 |
| 30 Sep 15 | 0 | -225 | 30 | 196 |
| 30 Jun 15 | 0 | -200 | 25 | 176 |
| 31 Mar 15 | 0 | -175 | 24 | 151 |
Quality Earnings: PBYI has high quality earnings.
Growing Profit Margin: PBYI's current net profit margins (17.4%) are higher than last year (9.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBYI has become profitable over the past 5 years, growing earnings by 73.3% per year.
Accelerating Growth: PBYI's earnings growth over the past year (59.1%) is below its 5-year average (73.3% per year).
Earnings vs Industry: PBYI earnings growth over the past year (59.1%) exceeded the Biotechs industry 52%.
Return on Equity
High ROE: PBYI's Return on Equity (32.1%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:10 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Puma Biotechnology, Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |